Cipla gets USFDA nod for generic cancer drug

Cipla has secured USFDA approval to market a generic version of Abraxane, paclitaxel protein-bound particles for injectable suspension (100 mg/vial). This medication is indicated for treating metastatic breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hv3QJnr
via IFTTT